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Abstract: Prothrombin time (PT) is the leading test for monitoring oral anticoagulation therapy (OAT). We sought to de-
termine INR taking into account only active coagulation factors FII, FVII and FX without inhibition in patient plasmas 
and calibrator kits. 
We measured PT using a combined thromboplastin reagent. The calculation was based on a new PT method, which meas-
ures active coagulation factors (F II, F VII, FX) and corrects the errors caused by inactive coagulation factors. 
On this basis, an INR result with and without inhibition for individual patient samples was also calculated and applied to 
200 plasma samples obtained from OAT patients. Conspicuous variation in inhibition between the four calibration kits 
was noted. The kinetics of this inhibition was closest to a noncompetitive pattern. 
The need of correction for INRs of single patients increases with higher INRs. At the same level of patient INRs the co-
agulation inhibiton varies markedly. 
It has been known that different thromboplastin reagents possess variable sensitivities, but this may depend on sensitivity 
in inactive coagulation factors. PT methods today measure the sum of active coagulation factors and inhibition of inactive 
coagulation factors. ISI calibrators contain variable amounts of inactive coagulation factors, which renders harmonisation 
of INR results. 
Application of the Acf-PT (INRAcf) presented in this work develops the PT methodology to measure the true coagulation 
activity in vivo for patient warfarin therapy without inhibition. INRInh can evidently also be used for the diagnostics and 
follow-up of certain liver diseases. 
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INTRODUCTION 
  Oral anticoagulation therapy (OAT) is - globally - one of 
the most widely used medications. The benefit of OAT has 
been proved in many clinical indications, but the major prob-
lem with it has been a narrow therapeutic window; overdos-
ing increases the risk of bleeding and less than optimal anti-
coagulation predisposes to thrombosis. The prothrombin 
time test (PT) was introduced by Quick more than 70 years 
ago. It has served as a basis for OAT monitoring from the 
beginning of this therapy. According to a recent review the 
problem with this test, however, has been the poor compara-
bility of results obtained in different laboratories [1]. An 
attempt to solve this problem was by the introduction In the 
mid-1980s of a universal means of harmonizing and report-
ing PT results. All thromboplastins should be calibrated in 
terms of the International Sensitivity Index (ISI) and the PT 
results given in INR (International Normalized Ratio) units 
[2]. In practice, standardization should be performed by 
comparing the results from test thromboplastin with those 
given by a reference thromboplastin calibrated in accordance 
with the method recommended by the WHO Expert Commit-
tee on Biological Standardization [2-3]. Unfortunately, an   
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increasing body of evidence indicates that this goal has not 
been achieved using manufactured and local calibrators [4-9]. 
  Many of the circumstances under which PT determina-
tion takes place are uncontrollable. These include - at least - 
that: (i) only a fraction of the blood components involved in 
the clotting reaction have been characterized [1]; (ii) differ-
ent reagents are known to vary with respect to source of 
thromboplastins and other reagent components [10], and 
(iii); that these have likewise not been characterized in detail. 
  In the present study we sought to establish whether PT 
results could be measured by determining PT times taking 
into account only active coagulation factors FII, FVII and 
FX, i.e., eliminating the effects of various coagulation inhibi-
tors. These factors lack gamma carboxyglutamic acid, which 
is necessary for calcium binding and thereby for “adsorp-
tion” of these factors to phospholipid surfaces. They are in-
active analogues to active coagulation factors [11-13], most 
of them obviously being PIVKA (Proteins Induced by Vita-
min K Absence or Antagonist ). PIVKAs are also circulating 
markers in hepatocellular carcinoma [14-15] and biliary cir-
rhosis [16] without warfarin therapy. 
MATERIALS AND METHODOLOGY 
Patients and Blood Sampling 
  Venous blood samples were obtained from 10 normal 
subjects and 210 hospital and health-centre patients for 
whom the PT time test was requested for the monitoring of 12    The Open Medicinal Chemistry Journal, 2008, Volume 2  Horsti et al. 
oral anticoagulant therapy. In our region a “P-INR” test code 
is used for this purpose. The patient samples thus represented 
all possible phases of anticoagulation: (i) before treatment, 
(ii) dose-adjusting phase, and (iii) steady- state phase. All 
procedures were approved by our institution’s responsible 
committee in accordance with the Helsinki Declaration of 
1975. Blood (1.8 mL) was drawn into citrate coagulation 
tubes (Greiner Labortechnik GmbH, Vacuette cat. no. 
454322, 9NC) containing 0.2 mL 0.109 mol/L (3.2 %) citrate 
solution. The sample needle (Terumo, Venoject needle, 
Quick Fit, cat. no. MN-2138MQ) was 0.8 x 40 mm. Sample 
tubes were centrifuged at 1850 g for 10 min at 20 
oC to sepa-
rate plasma. All measurements were commenced within 8 
hours of blood collection. 
PT Determination 
  The PT coagulation times were measured using a fully 
automated BCS coagulation analyser (DadeBehring Coagu-
lation System, DadeBehring, Marburg, Germany) and Owren 
PT method (combined thromboplastin reagent). The coagula-
tion reaction contained 10 L of citrated sample plasma, 60 
L of diluent and 140 L of reagent for normal PT meas-
urement and 5 l of citrated sample plasma 65 L of diluent 
and 140 L of reagent for patient and calibrator measure-
ments using the new PT method. Sample volumes were for 
"linear check": 15 l, 10 l, 8 l, 6l and 4 l and dilution 
factors: 0.67; 1.00; 1.25; 1.67; 2.50. 
  The test reagent was Nycotest PT, cat. no. 1002488 (rab-
bit brain thromboplastin) and a diluent (Nycotest PT, dilu-
tion liquid, cat.no. 1002485) from Axis-Shield as, lot 
10112954, ISI=1.07. 
ISI Calibration 
  Two local ISI calibrator kits were used: (i) “Svensk na-
tionell kalibrator för protrombinkomplexaktiviet”, from 
Equalis, lot 11, 12, Cal 1=0.85 INR and Cal 2=3.19 INR 
(used mainly in Sweden and Norway). (ii) “ISI-
kalibraattorikitti”, cat.no. B10000150, from Bioclin, lot 8, 
Cal 1=2.07 INR, Cal 2=3.52 INR and Cal 3=1.0 INR (used 
mainly in Finland). 
  Further, two commercial (“manufacturer calibration”) ISI 
calibration kits were used: (i) Etaloquick cat. no.00496 from 
Diagnostica Stago lot 041555. Cal 1=0.91 INR, Cal 2=3.24 
INR and Cal 3=4.90 INR. (ii) PT-Multi Calibrator cat.no. 
OPAT 035 from DadeBehring, lot 35422. Cal 1=1.01 INR, 
Cal 2=1.30 INR, Cal 3=1.65 INR, Cal 4=2.97 INR, Cal 
5=4.00 INR, Cal 6=5.29 INR. 
Determination of Minimal PT Time and Respective INR 
  The construction of a PT sec (Y-axis) versus C (where C 
is the dilution factor of normal plasma, OAT plasma, or cali-
brator) plot shows, at the intercept of the line obtained from 
the experiment and the X-axis, the so-called minimal clotting 
time (tmin) [17]. This latter is the clotting time which would 
be obtained under the conditions of the test in the presence 
of an infinite amount of the clotting factor, the inverse con-
centration of which is rendered on the X-axis. The inhibition 
effect can be calculated from the differences in intercepts of 
the unknown sample and normal plasma (or INR “zero” 
calibrator) (Fig. 1B). In practice, only two dilutions are re-
quired for each determination [17-21]. 
 
Fig. (1A). Model of the calculation of inhibition effect. 
  The inhibition principle on y axis is illustrated in Fig. 
(1A,B). We further calculated the difference in intercepts (= 
inhibition) also in INR units and subtracted it from total 
INRTot. 
INRAcf = INRTot – INRInh 
  INRs were calculated using the formula: INR = ( sample 
sec / normal sec )
ISI 
  Patent pending for method (EP 1861720, WO 
2006100346). 
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Fig. (1B). Model of intercept differences between patient plasma 
and normal plasma on y axis. The difference means inhibition as 
seconds and INR. 
Analytical Imprecision and Statistics 
  The within-run precision of PT tests was measured using 
one patient plasma sample (n = 10 determinations) with an 
INR value in the therapeutic range, i.e., approx. 2.2 INR. 
The respective CV was assessed 1.6 % for Nycotest PT.
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is consistent with our previous observations with a broader 
spectrum of reagents [9]. The Microsoft Excel 5.0 program 
was used to obtain the correlation functions and INR results. 
RESULTS 
  The coagulation time versus plasma (calibrator) dilution 
plots demonstrated a perfect linearity (Fig. 1B). Furthermore, 
the convergence pattern of lines demonstrated that the nature 
of the inhibition was closest to a non-competitive kinetics 
[20]. 
  Inhibition was demonstrable in all calibrators with INR 
values greater than 1. As expected, the inhibition increased 
concomitantly with the increase in calibrator INRs (Table 1). 
It is noteworthy, however, that the inhibition varied mark-
edly among the calibrator kits. 
  We further demonstrated that there was a difference - 
increasing towards higher INR values- between the tradi-
tional PT measurement and the new method measuring the 
active coagulation (INRAcf) in the case of the 200 OAT pa-
tients. Higher levels of anticoagulant medication decreases 
the amount of active coagulation factors and inhibition in-
creases proportionally. Individual original and corrected 
(INRAcf) values are illustrated (Fig. 2). The average for the 
traditional method was INR 2.68. After correction the aver-
age was 2.30 INR units, representing INRAcf. The current 
recommended target point for the OAT is now INR 2.50 (for 
the most indications 2.0-3.0 INR). The difference between 
methods is 0.38 INR in other words inhibition at 2.5 INR. 
These results allowed us to estimate the target point of 2.12 
INRAcf units, the range being 1.6-2.6 INRAcf for OAT. The 
individual variation in coagulation inhibition is notable at   
 
different INR levels for OAT patient samples as illustrated in 
Fig. (3) and Table 2. 
DISCUSSION 
  Harmonization of PT results and therapeutic ranges glob-
ally is an important goal. Equal results from different labora-
tories would be necessary for the reliable and safe adoption 
of results obtained by anticoagulation trials and for expert 
guidelines for treatment. Results from recent studies have 
unfortunately demonstrated that harmonization attempts 
have failed badly [1, 9]. Additional confirmation of this un-
acceptable situation was encountered in this investigation, 
where a tremendous bias between different calibrators was 
demonstrated. 
  The novel approach presented in this paper is based on 
studies performed by Hemker and co-workers in order to 
localize, in the coagulation cascade, the site of PIVKA inhi-
bition [19-21]. The authors [19-21] made careful studies and 
identified factor X analogues as the most important circulat-
ing anticoagulants among PIVKA. It is likely that the inhibi-
tion effect on factor X also has a central role in OAT plasma- 
and calibrator-induced inhibition of PTs. At the time in ques-
tion the PT results were given in seconds or as patient-PT-to-
reference-PT ratios. It was precisely the introduction of INR 
and WHO calibration for INR, which caused the problem of 
result harmonization for different regents and instruments. 
The recognition and admission of these inconsistencies is 
gradually gaining attention. May be this new PT method can 
help to harmonise INR results [22], because we eliminate the 
effect of inhibition upon measurement and calibration. 
  This method requires two measurements and a simple 
mathematical calculation for one patient sample. It is easy to  
 
Table 1.  INR Inhibition Obtained with Four Calibrator Kits Using the Owren PT Method (A Combined Thromboplastin Reagent) 
 
 Calibrator
a Calibrator  INR
b 
  INR Inhibition
c Active  INR
d Inhibition  (%) 
Multical 1  1.01  0.00  1.01  None 
Multical 2  1.30  0.04  1.26  3.29 
Multical 3  1.66  0.11  1.55  6.76 
Multical 4  2.93  0.29  2.64  9.74 
Multical 5  4.14  0.49  3.65  11.90 
Multical 6  5.46  1.12  4.34  20.43 
Etaloquick 1  1.00  0.00  1.00  None 
Etaloquick 2  2.85  0.31  2.54  10.78 
Etaloquick 3  4.25  1.00  3.25  23.59 
Bioclin 3  1.00  0.00  1.00  None 
Bioclin 1  2.07  0.32  1.75  15.36 
Bioclin 2  3.52  0.74  2.78  21.10 
Equalis 1  0.85  0.00  0.85  None 
Equalis 2  3.19  0.31  2.88  9.69 
aArranged according to increasing INR values. 
b INR given by the manufacturer. 
cThe inhibition was calculated by subtracting, in turn, the y-axis intercept (INR) value of each respective calibrator of the normal INR value (INR 1.0) from calibrators with higher 
values, i.e., containing inhibition. For details, see Materials and Methods and Fig. (1B). 
dThe active coagulation (INRAct) part of reaction with no inhibitors present. 14    The Open Medicinal Chemistry Journal, 2008, Volume 2  Horsti et al. 
 
 
Fig. (2). Traditional INR values determined by Owren PT, active coagulation factors (acf-INR) and inhibition effect for 200 OAT patient 
plasmas in increasing order using Etaloquick calibration. 
 
Fig. (3). Effect of inhibition (inhibitory factors FII, FVII and FX) on PTs in 200 OAT patient samples in increasing order. A New Generation PT Method  The Open Medicinal Chemistry Journal, 2008, Volume 2    15 
adapt for different kinds of instruments. The correction is 
needed for one sample individually and calibrators don’t 
need to contain coagulation inhibitors (normal plasma dilu-
tions), which helps and develops the global harmonisation of 
calibration. 
  In conclusion, today PT methods measure the sum of 
active coagulation factors and inhibition of inactive coagula-
tion factors. In principle calibrators should not contain in-
hibitory coagulation factors. The situation is the same using 
freshly pooled plasmas from normal 20 individuals and 60 
OAT patients for calibration according to recommendation 
[23], because OAT plasmas contain inactive coagulation 
factors too. Today we have "average inhibition" in PT cali-
bration, which causes disharmonisation using different 
thromboplastins and reagents. 
CONCLUSION 
  This new method gives true INRs for active coagulation 
factors and more accurate care for OAT patients. INRInh can 
evidently also be used for the diagnostics and follow-up of 
certain liver diseases [14-16]. Our hope is that this new ap-
proach, based on the INRAcf strategy, would revise the PT 
method and PT calibration using normal plasma. 
ABBREVIATIONS 
INR =  International  Normalized  Ratio 
ISI  =  International Sensitivity Index 
OAT =  Oral  anticoagulation  therapy 
PIVKA  = Proteins Induced by Vitamin K Absence or   
     Antagonist 
PT =  Prothrombin  time 
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Table 2.  Variation of Inhibition at Different INR Levels for OAT Patient Samples 
 
Inhibition n = 10  2 INR  3 INR  4 INR  5 INR  6 INR  Over 7 INR 
Average  0.22 0.37 0.41 0.49 0.49 0.76 
SD 0.05 0.11 0.15 0.21 0.15 0.22 
CV  %  24.41 29.41 36.09 43.57 30,11 28.71 